Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
Campaigners urge NHS to drop Roche acne drugCampaigners are demanding that the NHS stop prescribing Roche’s acne drug Roaccutane (isotretinoin), claiming it can lead to Share XCampaigners urge NHS to drop Roche acne drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-drop-roche-acne-drug/
Genentech signs deal with Parvus to tackle inflammatory diseasesCanada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for Share XGenentech signs deal with Parvus to tackle inflammatory diseaseshttps://pharmaphorum.com/news/genentech-signs-deal-with-parvus-to-tackle-inflammatory-diseases/
Roche’s entrectinib hits the mark in paediatric cancersRoche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an Share XRoche’s entrectinib hits the mark in paediatric cancershttps://pharmaphorum.com/news/roches-entrectinib-hits-the-mark-in-paediatric-cancers/
Roche and AbbVie’s Venclexta approved in CLLRoche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for Share XRoche and AbbVie’s Venclexta approved in CLLhttps://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/
The Pharma Social Media ConferencePharma Social Media Share XThe Pharma Social Media Conferencehttps://pharmaphorum.com/events/the-pharma-social-media-conference/
Market access round-up: the UK opens up to innovationWhen it comes to market access in the UK, the public’s eye has mostly been on the ongoing Share XMarket access round-up: the UK opens up to innovationhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-the-uk-opens-up-to-innovation/
NICE backs Ocrevus for PPMS in England – but with caveatsPatients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for Share XNICE backs Ocrevus for PPMS in England – but with caveatshttps://pharmaphorum.com/news/nice-backs-ocrevus-for-ppms-in-england-but-with-caveats/
NICE recommends Roche’s Tecentriq combo for certain lung cancer patientsCertain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made Share XNICE recommends Roche’s Tecentriq combo for certain lung cancer patientshttps://pharmaphorum.com/news/nice-recommends-roches-tecentriq-combo-for-certain-lung-cancer-patients/
